ESO-T01 delivers its first four multiple myeloma case reports.
ApexOnco Front Page
Recent articles
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.
Enzomenib might be the most promising agent so far, on a cross-trial basis.
Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.
The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.
And the company might one day follow Galapagos into decentralised manufacturing.
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
